Regeneron Currently Expects Its Q3 Financial Results Will Include An Acquired In-Process Research And Development (IPR&D) Charge Of $100M On Pre-tax Basis - Filing
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals expects its Q3 financial results to include an acquired In-Process Research and Development (IPR&D) charge of $100M on a pre-tax basis, according to a recent filing.
October 05, 2023 | 8:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron's Q3 financial results are expected to include a $100M pre-tax charge for acquired IPR&D. This could potentially impact the company's earnings.
The announcement of a $100M pre-tax charge for acquired IPR&D in Regeneron's Q3 results could potentially lead to a decrease in the company's earnings. This could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100